Loading
A phase 3 trial testing Sofetabart Mipitecan in ovarian cancer, now recruiting.
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer is a phase 3 interventional study registered as NCT07213804, led by Eli Lilly and with GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) and Asia-Pacific Gynecologic Oncology Trials, and recruiting on the registry. Official title: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. Planned enrolment is 1630 participants (estimated). The study started in 2025-10-22 and primary completion is expected in 2028-11. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/